Clínica Universidad de Navarra (CUN)
Centro clínico de la Universidad de Navarra
Hospital de Santa Maria
Lisboa, PortugalPublicaciones en colaboración con investigadores/as de Hospital de Santa Maria (22)
2024
-
Safety of pulsed field ablation in more than 17,000 patients with atrial fibrillation in the MANIFEST-17K study
Nature Medicine, Vol. 30, Núm. 7, pp. 2020-2029
2022
-
Clinical, histological and molecular profiling of different stages of alcohol-related liver disease
Gut, Vol. 71, Núm. 9, pp. 1856-1866
-
Early short course of neuromuscular blocking agents in patients with COVID-19 ARDS: a propensity score analysis
Critical Care, Vol. 26, Núm. 1
2021
-
Pressure injury prediction models for critically-ill patients should consider both the case-mix and local factors
Intensive and Critical Care Nursing
2020
-
International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)
Blood Cancer Journal, Vol. 10, Núm. 10
-
Major bleeding predictors in patients with left atrial appendage closure: The iberian registry ii
Journal of Clinical Medicine, Vol. 9, Núm. 7, pp. 1-11
-
Protein succination as a potential surrogate biomarker of airway obstruction. The ilervas project
Respiratory Medicine, Vol. 172
2019
-
Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas
Nature Communications, Vol. 10, Núm. 1
-
Long-term Event Reduction After Left Atrial Appendage Closure. Results of the Iberian Registry II
Revista Espanola de Cardiologia, Vol. 72, Núm. 6, pp. 449-455
2018
-
Efficacy and safety of lampalizumab for geographic atrophy due to age-related macular degeneration: Chroma and spectri phase 3 randomized clinical trials
JAMA Ophthalmology, Vol. 136, Núm. 6, pp. 666-677
-
Erratum to: The Intensive Care Global Study on Severe Acute Respiratory Infection (IC‑GLOSSARI): a multicenter, multinational, 14-day inception cohort study (Intensive Care Medicine, (2016), 42, 5, (953), 10.1007/s00134-016-4317-4)
Intensive Care Medicine
-
Heterogeneity within the PF-EPN-B ependymoma subgroup
Acta Neuropathologica, Vol. 136, Núm. 2, pp. 227-237
2017
-
Intertumoral Heterogeneity within Medulloblastoma Subgroups
Cancer Cell, Vol. 31, Núm. 6, pp. 737-754.e6
2016
-
Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under lendex: A longitudinal analysis
Blood, Vol. 127, Núm. 9, pp. 1151-1162
-
Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis
The Lancet Oncology, Vol. 17, Núm. 4, pp. 484-495
-
Therapeutic impact of cytoreductive surgery and irradiation of posterior fossa ependymoma in the molecular era: A retrospective multicohort analysis
Journal of Clinical Oncology, Vol. 34, Núm. 21, pp. 2468-2477
2015
-
Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up
British Journal of Haematology, Vol. 171, Núm. 3, pp. 344-354
2014
2013
-
Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma
Journal of Clinical Oncology, Vol. 31, Núm. 2, pp. 247-255
-
Suicidal ideation in a European Huntington's disease population
Journal of Affective Disorders, Vol. 151, Núm. 1, pp. 248-258